Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Despite a turbulent 2025, Ark Invest CEO Cathie Wood is currently sitting on a big win with her investment in Tempus AI ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Nancy Pelosi's newest stock bet, Tempus AI, remains an enticing buy following a promising Q1 2025 earnings report.

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...